Avacta Provides Q2 2025 Business Update
The biotechnology company provides a business update on the progress of its pipeline and changes to its management team and board.
The biotechnology company provides a business update on the progress of its pipeline and changes to its management team and board.
The biotechnology company has appointed a new Chief Medical Officer and a business development advisor to strengthen its leadership team.
The healthcare company has appointed Zeus Capital as a joint broker, joining existing brokers Peel Hunt and Panmure Liberum.
The life sciences company reports a new partial response in the dose expansion phase of its FAP-Dox Phase 1b trial for salivary gland cancer, a rare tumor type with high unmet need.
The life sciences company provides details on the availability of its annual report and revised notice for the upcoming annual general meeting.
The biopharmaceutical company reported widening losses and a significant revenue decline as it transitions to a pure-play oncology focus. Despite clinical progress, financial pressures and development risks loom large.
The healthcare company has pushed back the release of its preliminary results for the year ended December 31, 2024.
The healthcare company has appointed two experienced industry executives to its board of directors.
The healthcare company has pushed back the release of its preliminary results for the year ended December 31, 2024 due to audit work delays.
The biotechnology company will announce its audited preliminary results for the year ended December 31, 2024 and host an investor presentation on May 29, 2025.